Friday, August 23, 2024 |
| 7:00am |
Check-in and Breakfast in Exhibit Hall |
| 8:00am | Horizon CME App Overview |
| 8:10am | Welcome, Introductions, & CE Housekeeping |
| 8:15am | (01) The Daniel D. Von Hoff Keynote Lecture: Overcoming The Undruggable or Nature of the Most Common Human Oncogene KRas
» Kevan M. Shokat, PhD – Professor, Department of Cellular and Molecular Pharmacology UCSF Professor, Department of Chemistry, UC Berkeley, Investigator Howard Hughes Medical Institute, UCSF Helen Diller Family Comprehensive Cancer Center |
| 9:15am | Break | Refreshments in Exhibit Hall |
| | Block One: Small Molecules and Targeted Therapy |
| 9:40am | (02) Innovations in HER2 Targeted Therapy
» John H. Strickler, MD – Associate Professor of Medicine Associate Director Clinical Research – GI Duke University |
| 10:00am | (03) Clinical Advances in KRAS Targeting
» David S. Hong, MD – Douglas E. Johnson Endowed Professor Deputy Chair of the Department of Investigational Cancer Therapeutics [A Phase I Program] The University of Texas MD Anderson Cancer Center |
| 10:20am | (04) FGFR-targeted drugs
» Mitesh Borad, MD – Professor of Medicine Mayo Clinic College of Medicine and Science |
| 10:40am | (05) Targeting MTAP loss, a Synthetic Lethality Opportunity Hidden at Plain Sight
» Jordi Rodon Ahnert, MD, PhD – Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, Associate Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center |
| 11:00am | (06) Q+A Panel and Discussion: Block One
» Faculty for Sessions 02 – 05 |
| 11:20am |
Lunch |
| 12:20pm | Dessert – Refreshments in Exhibit Hall |
| | Block Two: Novel Approaches to Immunotherapy |
| 12:40pm | (07) New Oncolytic Viruses on the Horizon
» Dmitriy Zamarin, MD, PHD – Medical Oncologist, Icahn School of Medicine at Mount Sinai |
| 1:00pm | (08) The Emerging Landscape of Bispecifics in Drug Development
» Valentina Boni, MD, PhD – Medical Oncologist, Principal Investigator Director of Cancer Research NEXT Madrid Universitary Hospital Quironsalud Madrid |
| 1:20pm | (09) CAR-T Cell Targets in Solid Tumors and Enhanced CAR-T Cells
» Prasad S. Adusumilli, MD, FACS – Thoracic Surgeon, Cellular Therapist Memorial Sloan Kettering Cancer Center |
| 1:40pm | (10) NK Cell Therapy as a New Frontier in Cancer Treatment
» Katy Rezvani, MD, PhD – Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center |
| 2:00pm | (11) Novel Immunotherapy Targets and Combinations
» Antoni Ribas, MD, PhD – Professor of Medicine, Surgery, and Molecular and Medical Pharmacology University of California Los Angeles (UCLA), Director of the Tumor Immunology Program Jonsson Comprehensive Cancer Center (JCCC) Director, Parker Institute for Cancer Immunotherapy (PICI) Center |
| 2:20pm | (12) Q+A Panel and Discussion: Block Two
» Faculty for Sessions 07 – 11 |
| 2:40pm | Break – Refreshments in the Exhibit Hall |
| 3:00pm | Poster Session |
| | Block Three: Advances in Precision Oncology 2024 |
| 3:50pm | (13) Lung Cancers
» Hatim Husain, MD – Medical Oncologist, Associates Professor of Medicine, Moores Cancer Center at UC San Diego Health |
| 4:10pm | (14) Breast Cancers
» Philippe Bedard, MD, FRCPC – Medical Oncologist Princess Margaret Cancer Centre Associate Professor of Medicine University of Toronto |
| 4:30pm | (15) GI Cancers
» Hani Babiker, MD – Pancreaticobiliary, GI Oncology, Early Phase Therapeutics, and Senior Associate Consultant Mayo Clinic |
| 4:50pm | (16) GU Cancers
» Stephanie A. Berg, DO – Dana-Farber Cancer Institute, Genitourinary Medical Oncologist, Lank Center for Genitourinary Oncology |
| 5:10pm | (17) Q+A Panel and Discussion: Block Three
» Faculty from Sessions 13 – 16 |
| 5:30pm | Networking Reception – Exhibit Hall |
Saturday, August 24, 2024 |
| 7:00am |
Check-in and Breakfast in Exhibit Hall |
| 7:10am | Morning Breakfast Symposium – Sponsored by TBA
» TBA |
| 8:00am | Horizon CME App Overview |
| 8:05am | Welcome, Introductions, & CE Housekeeping |
| | Block Four: Biomarkers in Cancer |
| 8:10am | (18) ctDNA Applications in Management of Advanced Disease Patients on Investigational Agents
» Timothy Yap, MD – Professor, Department of Investigational Cancer Therapeutics (Phase I Program) Vice President, Head of Clinical Development, Associate Director, Translational Research, Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center |
| 8:30am | (19) AI as a Predictive Model in Drug Targets
» André Freitas, PhD – Associate Professor, University of Manchester Research Group Leader, Idiap Research Institute AI Group Leader, National Biomarker Centre, CRUK-MI |
| 8:50am | (20) Companion Diagnostic Development
» Kurt Schalper, MD, PhD – Associate Professor of Pathology, Director, Translational Immuno-oncology Laboratory, Yale School of Medicine |
| 9:10am | (21) Comprehensive Profiling
» Tim Greten, MD |
| 9:30am | (22) Q+A Panel and Discussion: Block Four
» Faculty from Sessions 18 – 21 |
| 9:50am | Break – Trivia for Charity in the Exhibit Hall |
| | Block Five: Clinical Trial Methodology |
| 10:30am | (23) Strategies for Patient enrollment
» Elmer Bernstam, MD, MSE – Reynolds and Reynolds Professor of Clinical Informatics Professor of Internal Medicine Associate Dean for Research, McWilliams School of Biomedical Informatics UTHealth Houston |
| 10:50am | (24) Early Phase Clinical Design in the Future
» Lillian L. Siu, MD, FRCPC – Medical Oncologist, Professor, Director of Phase I Program Princess Margaret Cancer Centre |
| 11:10am | (25) The Evolution of Agnostic Drug Approval: Where Are We Now?
» Gabe Sonke, MD, PhD – Internist, Professor, Oncology, Netherlands Cancer Institute |
| 11:30am | (26) Conduct of Early Phase Trials/Role of Patient Advocacy
» Melinda Bachini –Chief Patient Officer Cholangiocarcinoma Foundation |
| 11:50am | (27) Minority/Diversity Enrollment in Clinical Trials for Early Phase
» Owen Garrick, MD – Dean of Clinical Trials, Mayo Clinic |
| 12:10pm | (28) Q+A Panel and Discussion: Block Five
» Faculty from Sessions 23 – 27 |
| 12:30pm | Gather for Lunch |
| 12:40pm |
Buffet Lunch & Non-CME/CE Presentation Sponsored by TBA
» TBA |
| 1:30pm | Dessert Break in Exhibit |
| | Block Six: ADC |
| 1:50pm | (29) Pre-Clinical Considerations in ADC Development
» Daruka Mahadevan, MD, PhD – Professor of Medicine, Tenured, Chief, Division of Hematology/Medical Oncology, AT&T President’s Distinguished University Chair, Director, Institute for Drug Development, Associate Director Clinical Research Mays Cancer Center, University of Texas Health |
| 2:10pm | (30) Clinical Advances in ADC Development and Novel Payloads
» Anthony W. Tolcher, MD, FRCPC – Medical Oncologist, Co-founder of NEXT Oncology, Texas Oncology-San Antonio Babcock Next Oncology |
| 2:30pm | (31) Novel Combination Approaches for ADC Therapeutics
» Funda Meric-Bernstam, MD – Chair, Department of Investigational Cancer Therapeutics, Medical Director of the Institute for Personalized Cancer Therapy (IPCT), Professor in the Divisions of Cancer Medicine and Surgery, MD Anderson Cancer Center |
| 2:50pm | Break – Refreshments in the Exhibit Hall |
| 3:10pm | (32) Novel Targets
» Elena Garralda, MD – Medical Oncologist, Director, Early Drug Development Unit, Co-Director of VHIO’s Clinical Research Program, Dirertor of the Phase I Unit, Vrall d’Hebron Institute of Oncology, NEXT Oncology |
| 3:30pm | (33) Toxicity Management Considerations with Current ADC Landscape
» Toshio Shimizu, MD, PhD – Professor, Wakayama University Hospital/WMUH Cancer Center, Department of Pulmonary Medicine and medical Oncology, Wakayama Medical University Graduate School of Medicine |
| 3:50pm | (34) Q+A Panel and Discussion: Block Six
» Faculty from Sessions 29 – 33 |
| 4:10pm | Closing Comments |
